
Shares of vaccine maker Moderna MRNA.O rise 1.3% to $34.73 premarket
Company expects $1.9 billion in sales for 2025, which is near the upper end of its previously projected $1.6 billion to $2 billion range
MRNA cuts $200 million from 2025 operating expense forecast
Company is scheduled to report fourth-quarter and full 2025 results on February 13
Shares down 29.8% in 2025